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 28 
Abstract: 29 
Purpose:To assess early modifications in inner retinal layer (IRL) thickness and OCT 30 
angiography(OCT-A) parameters in patients with diabetes mellitus(DM) Type 1 and 2 31 
without clinical signs of diabetic retinopathy (DR).  32 
Methods:90 eyes of 90 subjects (24 Type 1 DM, 36 Type 2 DM and 30 healthy controls) 33 
were prospectively evaluated with SD-OCT,  swept-source OCT–A and color fundus photo 34 
(on the same day). Retinal nerve fiber layer(NFL), ganglion cell layer(GCL+) and 35 
NFL+GCL+ (GCL++)thickness were automatically determined by the instrument in the 1, 3 36 
and 6 central millimeters. On OCT-A, the following parameters were evaluated: area of 37 
foveal avascular zone(FAZ), number of microaneurysms, presence of: regular/irregular 38 
FAZ, capillary loss and capillary network irregularities in the superficial(SCP) and deep 39 
capillary plexuses(DCP). 40 
Results:GCL++ was thinner in DM Type 1 versus controls within 3mm. GCL+ (p=0.0099) 41 
and GCL++ (p=0.0367) were significantly thicker in DM type 1 vs DM Type 2 in 1 central 42 
mm.The area of FAZ was significantly larger: in DM Type 1 vs controls in both SCP and 43 
DCP and in DM Type 1 vs Type 2 only in DCP(p<0.05 for all); the number of 44 
microaneurysms was higher in DM Type 1 vs controls in both SCP and DCP (p<0.01 for 45 
all); and in DM type 2 vs controls only in DCP(p=0.007). Perifoveal capillary loss in SCP 46 
and IRL thickness had the highest correlation in both DM types. 47 
Conclusions:There are specific neural and microvascular modifications even before clinical 48 
signs of DR in DM type 1 and 2. In DM Type 1,both SCP and DCP were affected, whereas 49 
in DM Type 2 mostly DCP was affected. IRL thickness and perifoveal capillary loss in the 50 
SCP had the highest correlation. This data may help in characterization of patients at 51 
preclinical stage of DR. 52 
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 54 
Introduction: 55 
Diabetic retinopathy (DR) is the most important ocular complication in diabetes mellitus 56 
(DM). 1 Chronic hyperglycemia leads to increased oxidative stress, inflammation and 57 
hypoxia, all inducing alterations of the neurovascular unit of the retina. 2 The neurovascular 58 
unit of the retina consists of retinal neurons and glial cells, endothelial cells, and pericytes. 59 
2 All of these cell types undergo specific modifications induced by DM, even before the 60 
onset of clinical signs of DR, as reported by the experimental studies in animals and 61 
humans with DM. 3-8  62 
With recent advent of non invasive retinal imaging techniques such as spectral domain 63 
optical coherence tomography (SD-OCT) and  SD-OCT angiography, changes in thickness 64 
of single retinal layers as well as modifications of macular capillary network have been 65 
evaluated in patients with DM with or without DR. A decrease in retinal nerve fiber layer 66 
and ganglion cell layer has been reported in patients with DM, even without clinical signs 67 
of DR. 9-13 Alterations of the macular capillary network (especially foveal avascular zone 68 
enlargement and presence of areas of capillary loss in the perifoveal area in deep capillary 69 
plexus  and or superficial capillary plexus) have been reported in patients with DM without 70 
clinical signs of DR, when compared to subjects with no DM. 14-16  71 
There are very limited data on the direct evaluation and comparisons between 72 
microvascular changes detected on OCT angiography and retinal layer thickness changes 73 
in patients with DM and no clinical signs of DR. 15, 16 Dimitrova et al, evaluated changes in 74 
deep capillary plexus (DCP) and choroid in patients with DM Type 2 and no clinical signs 75 
of DR. 15  Simonett et al. evaluated a population of patients with DM Type 1 and no clinical 76 
signs of DM. 16 In this study we aimed to compare changes in inner retinal layer thickness 77 
and early microvascular changes detected on OCT angiography in patients with DM Type 78 
1 and DM Type 2 and no clinical signs of DR and compare to healthy controls. 79 
 4 
Material and Methods: 80 
 81 
Patients: 82 
This is a prospective, cross-sectional, comparative and consecutive case-control series of 83 
90 subjects (90 eyes), consisting of normal subjects (no DM) and patients with DM with no 84 
clinical signs of DR.  All subjects underwent blood pressure measurement, anamnestic 85 
collection of data including type of DM, value of haemoglobin A1c (HbA1c) complete 86 
ophthalmologic examination with best corrected visual acuity determination (BCVA), 87 
intraocular pressure (IOP) measurement, slit lamp fundus examination with 90D lens, color 88 
fundus photo of the macula, spectral domain optical coherence tomography (SD-OCT), 89 
and OCT angiography performed on the same day. Inclusion criteria were: patients with 90 
DM (type 1 and type 2, confirmed by the Diabetologist) with no clinical signs of DR 91 
determined on slit lamp fundus examination and confirmed on color fundus photo of the 92 
macula; healthy subjects (control group) and patients with DM older than 18 years; no 93 
history of ocular hypertension (IOP>21mmHg), glaucoma, uveitis, or neurodegenerative 94 
disease (for example Alzheimer disease, Parkinson, etc…); patients/subjects that 95 
accepted to participate.  Major exclusion criteria were: previous intraocular treatment 96 
(laser, intravitreal injections, vitreo-retinal surgery); cataract surgery within 6 months; any 97 
antiinflammatory/steroids topical therapy; refractive error >  +6D; any stage of DR or 98 
diabetic macular edema; and significant media opacity that precluded good quality fundus 99 
imaging and examination. The study was conducted in accordance with the tenets of the 100 
Declaration of Helsinki. All patients accepted to participate and signed the consent form.  101 
Visual acuity: 102 
Best-corrected distance visual acuity (BCVA) for each eye was measured by a certified 103 
tester using standard ETDRS protocol at 4 m distance with a modified ETDRS distance 104 
chart illuminator (Precise vision, Bloomington, IL). Visual acuity was scored as the total 105 
number of letters read correctly (ETDRS score) and (also expressed in logMar).  106 
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Imaging:  107 
Spectral domain optical coherence tomography and OCT-angiography: 108 
Spectral domain optical coherence tomography (SD-OCT) and OCT angiography were 109 
performed using the swept source OCT, DRI OCT Triton plus (Topcon Medical Systems 110 
Europe, Milano, Italy). This instrument uses a 1050nm wavelength, with a scanning speed 111 
of 100.000 A-Scans/second. Following scan-patterns were performed: a linear B-scan 112 
(12mm length) centered on the fovea at 0°; 3D Macula map covering central area of 7mm 113 
x 7mm; and OCT-angiography maps covering central 3mmx3mm area and 6mmx6mm 114 
area.  115 
SD-OCT Segmentation and measurement:  116 
DRI OCT Triton plus OCT instrument with software version 10.07.003.03 allows for 117 
automatic segmentation of following retinal layers from 3D map: retinal nerve fiber layer 118 
(NFL) from inner limiting membrane (ILM) to NFL; ganglion cell layer (GCL)+ complex – 119 
from NFL/GCL interface to inner plexiform layer (IPL)/inner nuclear layer (INL); GCL++ 120 
complex- from ILM/NFL interface to IPL/INL; outer retina- from IPL/INL interface to 121 
interdigitation zone (Verhoeff’s membrane); 17  (full) retina thickness- from ILM to 122 
interdigitation zone.  Automatic evaluation of the specific retinal layer thickness and full 123 
retinal thickness was performed in 9 ETDRS areas and evaluated as (central subfield 124 
retinal thickness (CSF) – circular area with 1 mm diameter centered on the fovea; inner 125 
rings (mean value of 4 inner quadrants with diameter of 3mm; and outer rings (mean value 126 
of 4 outer quadrants with 6 mm diameter). After automated segmentation, each scan was 127 
checked for the presence of segmentation errors, and in that case a manual correction 128 
was performed.  129 
OCT angiography scans evaluation: 130 
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OCT angiography (OCT-A) scans obtained within 3mmx3mm were used for both 131 
quantitative and qualitative evaluation. All evaluations were separately performed at the 132 
level of SCP and DCP. The built-in software segmentation algorithm was used to define 133 
SCP and DCP on En face OCT angiograms. The SCP slab was obtained from the ILM to 134 
15.6 micron above the IPL/INL interface. The DCP slab was obtained from the IPL/INL 135 
interface (above 15.6 micron)  to the IPL/INL interface (below 70.2 micron). Only good 136 
quality OCT-A images were considered for analyses, excluding those that had presence of 137 
artifacts such as double vessel pattern, dark areas from blinks, or motion artifacts, and 138 
those with signal strength index below 50.  139 
Following parameters were evaluated: 1) area of the foveal avascular zone (FAZ) 140 
delimitated using the tool caliper area available within software IMAGENET 6 (Version 141 
1.17.9720, Topcon Medical Systems, Inc, Oakland, NJ). After manual delimitation of the 142 
FAZ , the software automatically calculates the area in square milimeters (mm2); 2) 143 
number of microaneurysms counted within 3mm area; 3) presence of regular (oval or 144 
round shaped with regular and clear contour) 18 or irregular (asymmetrical) FAZ 4) 145 
presence of area of capillary loss/reduced capillary density; 5) alterations of the capillary 146 
network (presence of  tortuosity and/or beadings). 147 
All measurements and evaluations were performed by two graders, independently, 148 
masked to the clinical data of patients, on 3 mm scan area, zooming the image in order to 149 
have greater magnification and evaluate more easily details,  and (if necessary) using also  150 
the reverse mode (in which vessels are black and the background is white, for better 151 
definition of details). In case of disagreement the experienced medical retina specialist 152 
made a final adjudication.  153 
Statistical methods: 154 
 155 
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The summary of parameters has been made by means of usual methods used for 156 
descriptive statistics: mean value, standard deviation, and range for continuous numeric 157 
variables; frequency distribution, absolute and relative (percentage), for qualitative 158 
variables. 159 
 160 
Sample characteristics (age, systolic pressure, diastolic pressure, HbA1c, BCVA, and IOP) 161 
have been compared between patients with DM and controls by means of t-Student test. 162 
Comparisons among groups (DM Type 1 and DM Type 2, and controls) have been made 163 
by means of one-way Analysis of Variance (ANOVA) followed by post-hoc Bonferroni test 164 
for multiple comparisons. 165 
OCT parameters: 166 
Mean values of retinal thickness (full retinal thickness, NFL thickness, GCL+ thickness, 167 
GCL++ thickness, and Outer Retinal thickness) have been compared between patients 168 
with DM and controls, and among DM type 1, DM type 2, and controls by means of three 169 
factor with interaction ANOVA for repeated measures analysis, adjusted for age. 170 
Comparison between DM Type 1 and DM Type 2 has been adjusted also for the duration 171 
of DM. Retinal thickness determined in the 9 ETDRS quadrants was summarized into 172 
three values referred as CSF (central sub-field quadrant), inner ring (average value of 173 
inner superior, inner nasal, inner inferior, and inner temporal quadrant values), and outer 174 
ring (average value of outer superior, outer nasal, outer inferior, and outer temporal 175 
quadrant values). Factors of the model were Group (patients with DM and Controls in one 176 
analysis, DM Type 1, DM Type 2, and Controls in the other), Sector (CSF, inner ring, and 177 
outer ring), and the interaction Group by Sector. However particular interest has been 178 
placed to significance of Group factor (which tested differences among overall mean 179 
retinal thicknesses) and to interaction factor (which tested differences among retinal 180 
thickness profiles). Comparisons have been adjusted for patient’s age and in case of 181 
 8 
significant result, post-hoc tests for multiple comparisons with Bonferroni correction were 182 
applied. 183 
 184 
OCT Angiography parameters: 185 
Mean values of FAZ area extension and number of microaneurysms in the SCP and DCP  186 
have been compared among groups (patients with DM vs. controls, and DM Type 1 vs. 187 
DM Type 2 vs. controls) by means of one-way ANOVA analysis adjusted for patient’s age 188 
and blood pressure and followed by Bonferroni post-hoc test for multiple comparisons. 189 
Association between Group and presence of regular/irregular FAZ, presence of area of 190 
capillary loss/reduced capillary density, and presence of tortuosity/beadings have been 191 
assessed by means of logistic regression model adjusted for patient’s age and blood 192 
pressure. Association was expressed in terms of Odds-Ratios and relative 95% Wald 193 
confidence interval. 194 
 195 
Correlations among OCT and OCT Angiography parameters: 196 
Multiple linear regression models with stepwise selection of independent variables have 197 
been used to assess the relationship between retinal thickness (dependent variable) – one 198 
model for each parameters: full retina thickness, NFL layer, GCL+, GCL++, and Outer 199 
retinal thickness – and OCT Angiography parameters. Patient’s age and blood pressure 200 
(systolic and diastolic) were taken into account. Three models have been estimated, one 201 
for each of the following sectors: CSF, inner ring, and CSF plus inner ring. Qualitative 202 
variables have been coded as follows before entering the model: FAZ regularity, 203 
0=regular, 1=irregular; Capillary loss, 0=absent, 1=present, Tortuosity/Beadings, 204 
0=absent, 1=present. 205 
 206 
All the analyses have been performed by means of SAS® v.9.3 (SAS, Cary, NC) statistical 207 
software. All statistical tests have been considered significant when P<0.05. 208 
Results: 209 
 9 
 210 
Of 90 examined subjects (90 eyes), 60 were patients with DM with no clinical signs of DR 211 
and 30 were healthy subjects (with no DM). Of 60 patients with DM, 24 patients had DM 212 
Type 1 and 36 patients had DM Type 2 (of which 9 patients were on insulin whereas 27 213 
were oral hypoglycemic drugs). Systemic and ocular findings (mean age, HbA1c, duration 214 
of DM, blood pressure, BCVA and IOP values) are reported in Table 1.   215 
Table 2 shows mean values of retinal thickness (automatically measured by the 216 
instrument) of full retina, NFL, GCL+ complex, GCL++ complex and outer retina divided by 217 
rings (CSF, inner ring and outer ring) and groups (normal subjects, all patients with DM 218 
and separately DM type 1 and DM type 2). After adjusting for age there was a different 219 
thickness profile in GCL++ complex among three examined groups (control, patients with 220 
DM type 1 and DM type 2), p=0.049, (ANOVA) in the three different rings. Such a model 221 
estimated that GCL++ complex in the inner ring was thinner in patients with DM Type 1 222 
(114.9μm+8.3) versus controls with borderline statistical significance (118.0μm+8.2, 223 
Bonferroni post-hoc test for multiple comparison, p=0.0981).   224 
After adjusting for age and DM duration, GCL+ complex (49.4μm+7.3 vs. 43.6μm +9.6, 225 
p=0.0099) and GCL++ complex (57.2 μm+10.8 vs. 50.5+10.2 μm, p=0.0367) were 226 
significantly thicker in patients with DM type 1 vs DM Type 2 in the CSF (Table 2). 227 
Table 3 shows data of parameters evaluated on OCT angiography, adjusted for patient’s 228 
age and blood pressure. All evaluated parameters both quantitative and qualitative were 229 
significantly different in patients with DM versus controls in both SCP and DCP. (Table 3). 230 
In particular, the area of FAZ was significantly larger: in patients with DM Type 1 versus 231 
controls in both SCP (p=0.05) and DCP (p<0.001) and in patients with DM Type 1 versus 232 
DM Type 2 only in DCP (p<0.0001); the number of microaneurysms was higher in patients 233 
with DM Type 1 versus controls in both SCP (p<0.001) and DCP (p<0.0001); and in 234 
patients with DM type 2 versus controls only in DCP (p=0.007). (Table 3) Logistic 235 
regression analysis (adjusted for patient’s age and blood pressure), showed greater 236 
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association between all evaluated qualitative parameters in patients with DM type 1 and 237 
almost all (exception for irregularities in the SCP) for patients with DM type 2 versus 238 
control group. (Table 3) 239 
Table 4 shows statistically significant correlations between OCT and OCT angiography 240 
parameters. Statistically significant correlations to retinal thickness include almost all 241 
parameters evaluated on OCT angiography in the SCP in patients with DM type 1, 242 
whereas only the presence of areas of capillary loss and FAZ area in the SCP in patients 243 
with DM type 2. In particular, the area of FAZ in SCP inversely correlated to NFL thickness 244 
in the CSF in patients with DM type 2 whereas, the area of FAZ in DCP inversely 245 
correlated to NFL thickness in the CSF in patients with DM type 1.  246 
The highest correlations were found between perifoveal capillary loss in the SCP and 247 
GCL+  and GCL++ thickness in the inner ring in patients with DM Type 1 and perifoveal 248 
capillary loss in the SCP and NFL thickness in the CSF and the inner ring in patients with 249 
DM Type 2. 250 
Discussion: 251 
In this study we report on early microvascular and retinal thickness changes in patients 252 
with DM and no clinical signs of DR, evaluating further and separately patients with DM 253 
Type 1 and DM Type 2 vs healthy subjects. All quantitative and qualitative parameters 254 
evaluated on OCT-A in the SCP and DCP were significantly different in patients with DM 255 
versus healthy controls. In particular, in patients with DM and no clinical signs of DR, FAZ 256 
area was larger and irregular, the number of microaneurysms was higher, areas of 257 
perifoveal capillary loss and perifoveal capillary network irregularities (such as tortuosity 258 
and beadings) were more numerous in both SCP and DCP when compared to healthy 259 
subjects. Simonett et al. evaluated patients with DM type 1 and no DR (9 eyes) or mild non 260 
proliferative DR (19 eyes) and reported decreased parafoveal vessel density (that could be 261 
compared to parafoveal capillary nonperfusion) only in the DCP, and no changes in the 262 Formattato: Inglese (Stati Uniti)
 11 
FAZ area were found in neither SCP nor DCP. 16  Dimitrova at al. documented decreased  263 
parafoveal vessel density  in the SCP and DCP and FAZ area increase in the SCP in 264 
patients with DM (mostly type 2) and no DR when compared to control subjects. 15 265 
In the present study, specific changes are documented separately in patients with DM 266 
Type 1 and DM Type 2. All quantitative and qualitative parameters evaluated on OCT 267 
angiography resulted altered in both SCP and DCP in patients with DM type 1 vs controls. 268 
In DM type 2, the only quantitative parameter found different, compared to controls, was  269 
the higher number of microaneurysms in the DCP. Thus, the other evaluated quantitative 270 
parameters (the area of the FAZ in SCP and DCP and the number of microaneurysms in 271 
SCP) were not found different in patients with DM type 2 vs controls. Moreover, the area of 272 
the FAZ was significantly larger in patients with DM type 1 vs patients with DM type 2 in 273 
the DCP. Besides modifications in quantitative parameters, also all evaluated qualitative 274 
parameters were found different in patients with DM type 1 vs controls, and almost all 275 
(except the presence of capillary irregularities in the SCP) in patients with DM type 2 276 
compared to controls. Although data from the present study cannot be directly correlated 277 
to the data available in the literature on OCT angiography parameters in patients with DM 278 
and no clinical signs of DR, due to different population of patients (considering together 279 
patients with DM type 1 and 2, or only separately patients with DM type 1 but also with 280 
some signs of DR), some similarities or differences could be drawn.  De Carlo et al. 281 
reported on  increased prevalence in changes to the FAZ (increased FAZ area and 282 
presence of FAZ remodeling) and capillary nonperfusion in patients with DM (considering 283 
together type 1 and type 2) and no clinical signs of DR. 14 The same authors reported that 284 
vascular tortuosity was present in similar percentage in both controls and patients with 285 
DM, concluding that this microvascular abnormality may be a variant of normal, and thus 286 
cannot be used as the OCT-A screening parameter for retinal vascular change in DM. 14 287 
However, the authors did not report on blood pressure data and differences between the 288 
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groups. On the contrary, in the present study, after adjusting for blood pressure differences 289 
both venous beading and vascular tortuosity were found more frequent in patients with DM 290 
type 1 and DM type 2 versus non diabetic subjects. Thus the significance of microvascular 291 
abnormalities in patients with DM and no clinical signs of DR may warrant further 292 
evaluation. 293 
Results from the present study confirm data reported by Dimitrova et al, who found 294 
changes  in parafoveal vessel density in both SCP and DCP in patients with DM (mostly 295 
type 2) and no clinical signs of DR. 15 Simonett et al, evaluated a cohort of 28 patients with 296 
DM type 1 and no or minimal signs of DR using an automated algorithm software. 16 These 297 
Authors reported a decrease in parafoveal vessel density only in the DCP. 16 Choi et al, 298 
using an ultrahigh speed swept source OCT angiography prototype, documented retinal 299 
microvascular abnormalities (such as capillary dropout, dilated capillary loops, tortuous 300 
capillary branches, patches of reduced capillary perfusion, irregular FAZ contours, and/or 301 
FAZ enlargement) in both SCP, intermediate and DCP, in 18 of the 51 eyes with DM and 302 
no clincial signs of DR (with no specification of DM type). 19 Moreover, these Authors 303 
reported focal or diffuse choriocapillaries flow impairment in almost half of the evaluated 304 
patients without DR.  305 
Data from the present study may indicate that both SCP and DCP are precociously altered 306 
in patients with DM type 1 and no clinical signs of DR, whereas in patients with DM type 2, 307 
DCP is more precociously involved. To the best of our knowledge, no data are currently 308 
available on direct comparison between patients with DM type 1 and type 2 at pre-clinical 309 
stage of DR.  310 
 311 
Patients with DM type 1 had thinner inner parafoveal retinal thickness (GCL++ complex in 312 
the inner ring) when compared to normal subjects (when adjusted for age). Scarinci et al, 313 
recently reported a significant thinning of the GCL layer in patients with DM type 1 and no 314 
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DR. 13 Van Dijk et al documented no significant difference in any layer thickness in the 315 
macula in patients with DM but no DR compared to normal controls and a decrease in the 316 
NFL, GCL and IPL thickness in the pericentral area of the macula, in patients with minimal 317 
DR compared to controls 10 Vujosevic and Midena documented  decreased NFL thickness 318 
in the macular area in patients with no DR or with non proilferative DR, mostly with DM 319 
type 2. 11 In the present study, after adjusting for age and DM duration, GCL+ and GCL++ 320 
complex thicknesses were significantly higher in patients with DM type 1 vs DM Type 2 in 321 
the CSF. The exact mechanism leading to this finding is not known. One hypothesis may 322 
implicate a protective role of more intensive insulin treatment on retinal ganglion cells 323 
already reported in experimental studies, thus thicker inner retina in DM type 1.20, 21 324 
Another hypothesis may see reported differences in complication characteristics in 325 
patients with DM type 2 versus DM type 1, that included more prevalent peripheric 326 
neuropathy and cardiovascular disease in DM type 2, independent of disease duration, 327 
whereas no differences were found for the presence of DR. 22 This may explain thinner 328 
inner retina in DM type 2 when corrected for age difference and DM duration in the present 329 
study. 22 330 
In conclusion this study documents very early and specific microvascular and neuronal 331 
changes both in patients with DM type 1 and DM type 2, when compared to non diabetic 332 
controls. OCT-A allows for detection of microvascular changes even before clinical signs 333 
of DR are present. Thus, OCT-A may help in earlier diagnosis and new classification of 334 
DR. Further, larger studies are needed to better evaluate and correlate microvascular and 335 
neural changes in the retina in DM. 336 
 337 
 338 
 339 
 340 
 341 
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 446 
Figures’ Legend: 447 
Figure 1. 448 
Right eye of a patient with diabetes mellitus type 1 and no clinical signs of 449 
diabetic retinopathy. First raw: Left - color fundus photo; middle-OCT-450 
angiography (OCT-A) of the superficial capillary plexus (SCP); right- OCT-451 
angiography of the deep capillary plexus (DCP); modifications of the foveal 452 
avascular zone-FAZ including enlaragment and presence of irregular form 453 
presence of area of capillary loss/reduced capillary density,  and alterations of 454 
the capillary network are present both the SCP and DC; Second raw: OCT linear 455 
scan  in the macula showing automatic segmentation (green lines) of the nerve 456 
fiber layer; ganglion cell layer (GCL)+ complex – from NFL/GCL interface to 457 
inner plexiform layer (IPL)/inner nuclear layer (INL); GCL++ complex- from 458 
ILM/NFL interface to IPL/INL; outer retina- from IPL/INL interface to 459 
interdigitation zone. 460 
 461 
Figure 2. 462 
Right eye of a patient with diabetes mellitus type 1 and no clinical signs of 463 
diabetic retinopathy. First raw: Left - color fundus photo; middle-OCT-464 
angiography (OCT-A) of the superficial capillary plexus (SCP); right- OCT-465 
angiography of the deep capillary plexus (DCP); enlargament of the foveal 466 
avascular zone as well as the presence of microaneurysm is better observed in 467 
the DCP. presence of area of capillary loss/reduced capillary density,  and 468 
alterations of the capillary network are present both the SCP and DC; Second 469 
raw: OCT linear scan  in the macula showing automatic segmentation (green 470 
lines) of the nerve fiber layer; ganglion cell layer (GCL)+ complex – from 471 
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NFL/GCL interface to inner plexiform layer (IPL)/inner nuclear layer (INL); 472 
GCL++ complex- from ILM/NFL interface to IPL/INL; outer retina- from IPL/INL 473 
interface to interdigitation zone. 474 
 475 
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Table 1 – Sample characteristics. Mean (SD, range) 500 
Variable 
Controls 
(N=30)  
Diabetics 
(N=60)  
Diabetes 
Type I 
(N=24)  
Diabetes 
Type II 
(N=36) 
Age 
44.4 
(14.8, 21-72) 
 57.4a 
(15.4, 19-81) 
 36.9 
(12.1, 19-53) 
 64.2e,f 
(8.9, 41-81) 
HbA1c 
n.a.  7.3 
(1.0, 5.8-10.3) 
 7.2 
(0.9, 5.9-9.1) 
 7.3 
(1.1, 5.8-10.3) 
Duration 
n.a.  9.9 
(8.7, 0.5-40) 
 16.3 
(11.3, 2-40) 
 7.7d 
(6.4, 0.5-21) 
SBP 
120.2 
(8.9, 90-130) 
 126.1b 
(10.0, 100-150) 
 119.2 
(11.6, 100-140) 
 128.5g,h 
(8.3, 120-150) 
DBP 
76.7 
(7.8, 60-90) 
 77.3 
(5.8, 60-85) 
 73.3 
(8.1, 60-85) 
 78.6i 
(4.2, 70-85) 
ETDRS 
85.0 
(0.0, 85-85) 
 83.6 
(4.3, 55-88) 
 84.9 
(0.3, 84-85) 
 82.8j 
(5.4, 55-88) 
IOP 
14.6 
(2.1, 12-19) 
 13.9c 
(1.2, 12-18) 
 13.2k 
(1.1, 12-15) 
 14.3l 
(1.0, 13-18) 
Legend: Duration=duration of diabetes (years); SBP=systolic blood pressure (mmHg); DBP=diastolic blood 
pressure (mmHg); ETDRS=number of letters; IOP=intraocular pressure (mmHg); n.a.=not 
applicable. Diabetics vs. Controls t-Student test: a) P=0.0010; b) P=0.0161; c) P=0.0315. Bonferroni post-hoc 
test: d) Type I vs. Type II , P=0.0020; e) Type II vs. Controls, P<0.0001;  f) Type II vs. Type I, P<0.0001; 
g) Type II vs. Controls, P=0.0029; h) Type II vs. Type I, P=0.0092;  i) Type II vs. Type I, P=0.0425; j) Type II vs. 
Controls, P=0.0326; k) Type I vs.Controls, P=0.0020;  l) Type II vs. Type I, P=0.0143. 
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Table 2 – Retinal thickness. Mean (SD) 531 
Parameter 
Controls 
(N=30)  
Diabetics 
(N=60)  
Diabetes 
Type I 
(N=24)  
Diabetes 
Type II 
(N=36) 
Total thickness        
   CSF 243.2 (21.4)  238.4 (20.9)  241.2 (20.1)  236.5 (21.5) 
   Inner ring 313.0 (12.2)  307.7 (16.1)  309.1 (16.5)  306.8 (16.0) 
   Outer ring 273.0 (12.9)  267.0 (13.0)  268.9 (12.8)  265.8 (13.2) 
NFL layer        
   CSF 7.3 (3.6)  7.3 (3.3)  8.0 (3.6)  6.8 (3.1) 
   Inner ring 27.0 (2.0)  26.9 (2.4)  26.4 (1.3)  27.1 (2.9) 
   Outer ring 40.5 (2.9)  39.6 (3.3)  39.4 (2.7)  39.8 (3.7) 
GCL+ layer        
   CSF 47.6 (8.7)  46.0 (6.7)  48.7C (6.1)  44.1 (6.5) 
   Inner ring 92.7 (5.4)  90.0 (6.7)  90.2a (7.2)  89.8 (6.5) 
   Outer ring 66.5 (3.8)  65.2 (5.3)  66.1 (4.4)  64.6 (5.8) 
GCL++ layes        
   CSF 54.8 (12.0)  53.2 (9.2)  56.8D (9.0)  50.9 (8.6) 
   Inner ring 119.7 (6.8)  116.8 (8.2)  116.7b (7.9)  116.9 (8.4) 
   Outer ring 107.0 (5.2)  104.8 (7.3)  105.6 (6.5)  104.3 (7.8) 
Outer retina        
   CSF 188.3 (11.5)  185.2 (14.2)  184.5 (13.2)  185.6 (15.1) 
   Inner ring 193.3 (7.2)  190.9 (10.3)  192.5 (10.9)  189.9 (9.8) 
   Outer ring 165.9 (8.6)  162.2 (8.6)  163.3 (9.9)  161.5 (7.6) 
 532 
Legend:NFL: retinal nerve fiber layer; GCL+ - ganglion cell layer; GCL++- NFL and GCL+ ; 533 
CSF: central subfield retinal thickness; inner ring- retinal thickness within central 3mm; 534 
outer ring: retinal thickness within central 6mm.535 
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Table 3 – OCT-Angiography parameters. 537 
Parameter 
Controls 
(N=30)  
Diabetics 
(N=60)  
Diabetes 
Type I 
(N=24)  
Diabetes 
Type II 
(N=36) 
FAZ area1        
   Superficial plexus 286.4 (137.0)  359.3a (129.1)  377.2e (150.6)  347.5 (113.2) 
   Deep plexus 363.7 (142.1)  497.0b (150.3)  557.1f,g (139.6)  456.9 (145.9) 
Number of microaneurisms1        
   Superficial plexus 0.10 (0.40)  1.40c (1.61)  1.38h (2.10)  1.42 (1.20) 
   Deep plexus 0.07 (0.37)  2.07d (1.89)  1.83i (2.16)  2.22j (1.71) 
Irregular quality2        
   Superficial plexus 17 (56.7)  50A (83.3)  21G (87.5)  29 (80.6) 
   Deep plexus 8 (26.7)  50B (83.3)  23H (95.8)  27M (75.0) 
Capillary loss2        
   Superficial plexus 12 (40.0)  55C (91.7)  22I (91.7)  33N (91.7) 
   Deep plexus 7 (23.3)  58D (96.7)  23J (95.8)  35O (97.2) 
Presence of Tortuosity/Beadings2        
   Superficial plexus 1 (3.3)  47E (78.3)  14K (58.3)  33P (91.7) 
   Deep plexus 3 (10.0)  54F (90.0)  19L (79.2)  35Q (97.2) 
Legend: 1) Mean (standard deviation); 2) Frequency (%). ANOVA adjusted for patient’s age and 538 
blood pressure, test vs. Control group: a) P=0.0582; b) P=0.0003; c) P=0.0005; d) P<0.0001. Post-539 
hoc Bonferroni test vs. Control group after ANOVA adjusted for patient’s age and blood pressure: 540 
e) P=0.0189; f) P<0.0001; g) vs. Type II group, P=0.0012; h) P=0.0013; i) P<0.0.001; j) P=0.0118. 541 
Logistic regression analysis adjusted for patient’s age and blood pressure, Odds-Ratios (95%CI) 542 
vs. Control group: A) 4.0 (1.3 to 11.7); B) 22.0 (6.0 to 81.5); C) 13.1 (3.8 to 44.3); D) 87.5 (14.8 to 543 
517.2); E) 97.1 (11.0 to 858.3); F) 168.1 (19.0 to +∞); G) 5.6 (1.3 to 23.0); H) 68.2 (7.7 to 606.9); I) 544 
27.9 (4.4 to 177.1); J) 179.3 (12.6 to +∞); K) 68.3 (6.4 to 788.2); L) 352.4 (16.3 to +∞); M) 8.9 (1.9 545 
to 42.4); N) 5.4 (1.0 to 29.8); O) 36.9 (3.5 to 389.5); P) 136.8 (11.7 to +∞); Q) 87.7 (7.3 to +∞). 546 
 547 
 548 
 549 
 550 
 551 
552 
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Table 4 – Correlation between OCT parameters and OCT-Angiography parameters. 553 
Quadrant Total thickness NFL layer GCL+ layer GCL++ layer Outer retina 
Controls      
CSF FAZs (-0.145) FAZd (-0.020) 
CAPd (+2.516) 
FAZs (-0.036) 
FAZd (-0.023) 
FAZs (-0.046) 
FAZd (-0.036) 
FAZs (-0.073) 
QUAd (-6.692) 
Inner FAZs (-0.060) 
QUAs (-8.472) 
FAZd (-0.008) FAZs (-0.026) 
QUAs (-2.695) 
TORd (+7.891) 
FAZs (-0.033) 
QUAs (-3.748) 
FAZs (-0.030) 
QUAs (-4.653) 
CSF+Inner FAZs (-0.082) 
QUAs (-6.930) 
FAZd (-0.011) FAZs (-0.031) 
TORd (+7.016) 
FAZd (-0.043) 
QUAs (-2.938) 
FAZs (-0.038) 
QUAd (-3.968) 
DM      
CSF FAZs (-0.069) 
MICd (-3.487) 
FAZs (-0.009) 
TORs (-2.552) 
FAZs (-0.021) 
MICs (+1.427) 
MICd (-1.110) 
TORs (-6.681) 
TORd (+5.111) 
FAZs (-0.031) 
TORs (-7.267) 
FAZd (-0.036) 
MICd (-2.576) 
QUAd (+7.720) 
Inner MICd (-2.627) FAZd (-0.003) 
CAPs (-2.307) 
FAZs (-0.019) FAZs (-0.023) MICd (-1.764) 
CSF+Inner FAZs (-0.033) 
MICd (-2.456) 
FAZd (-0.004) 
QUAd (+1.390) 
CAPs (-2.601) 
FAZs (-0.020) FAZs (-0.022) 
TORs (-3.818) 
MICd (-2.075) 
Type I      
CSF FAZd (-0.083) FAZd (-0.013) FAZd (-0.027) FAZd (-0.038) MICs (-3.357) 
Inner MICs (-2.899) QUAs(-1.835) 
TORs (-1.114) 
CAPs (-10.273) CAPs (-11.011) - 
CSF+Inner MICs (-3.305) MICs (-0.357) CAPs (-8.936) MICs (-1.522) MICs (-1.783) 
Type II      
CSF FAZs (-0.119) 
MICd (-3.853) 
FAZs (-0.009) 
CAPs (-4.401) 
FAZs (-0.042) FAZs (-0.056) FAZs (-0.067) 
MICd (-3.749) 
Inner FAZd (-0.041) 
MICd (-2.995) 
CAPs (-4.053) FAZd (-0.022) FAZd (-0.027) MICd (-2.766) 
CSF+Inner FAZs (-0.067) 
MICd (-3.456) 
CAPs (-4.388) FAZd (-0.023) FAZs (-0.038) FAZs (-0.029) 
MICd (-2.912) 
 
 
 
 
Legend: In brackets statistically significant (P<0.05) regression coefficients from the 
multiple regression model of each OCT parameter vs. Angio-OCT parameters (stepwise 
selection criterion) adjusted for patient’s age and blood pressure (systolic and diastolic). 
FAZ = extension of area of the foveal avascular zone FAZ (mm2); MIC = microaneurysms 
(number); QUA = quality of the FAZ area (0=regular,1=irregular; CAP = capillary loss 
(0=no, 1=yes); TOR = presence of tortuosity/beadings (0=no, 1=yes); suffix ‘s’ = superficial 
plexus; suffix ‘d’ = deep plexus. CSF = central subfield retinal thickness; Inner = the mean 
of superior, nasal, inferior and temporal inner quadrant thickness (central 3mm); 
CSF+Inner = the average of CSF and Inner quadrants’ thickness. 
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